Fri, March 27, 2020

Benjamin Burnett Upgraded (BLUE) to Strong Buy and Decreased Target to $70 on, Mar 27th, 2020

Benjamin Burnett of Stifel, Upgraded "bluebird bio, Inc." (BLUE) to Strong Buy and Decreased Target from $94 to $70 on, Mar 27th, 2020.

Benjamin has made no other calls on BLUE in the last 4 months.



There are 4 other peers that have a rating on BLUE. Out of the 4 peers that are also analyzing BLUE, 1 agrees with Benjamin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Wednesday, February 26th, 2020


These are the ratings of the 3 analyists that currently disagree with Benjamin


  • Joshua Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy and Increased Target to $100 on, Monday, February 3rd, 2020
  • Mark Breidenbach of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $135 on, Friday, December 13th, 2019
  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $160 on, Monday, December 9th, 2019